Chronic spontaneous urticaria treated with omalizumab: report of two cases

AbstractChronic spontaneous urticaria (CSU) is a relatively common skin disease whose etiopathogenesis, as well as other factors influencing disease manifestations, are not fully understood. Mast cell function is recognised as having a central role in CSU signs and symptoms.Therapeutic options are limited; a number of drugs, recommended by international guidelines for the management of urticaria, lack regulatory approval for CSU and are prescribed off label.Omalizumab, a recombinant humanized anti IgE antibody, has recently received the approval for CSU treatment in Europe after an appropriate clinical development. Two case reports, that describes our encouraging experience with this therapeutic option in a real-life setting are discussed and deeply investigate the different scenario for the omalizumab use.In both cases, a complete remission of CSU symptoms after omalizumab treatment are demonstrated.Moreover, 6 months therapy gave the better results, whit a relapse, in one subject, 1 month after disconti...